• 1
    Safety update on TNF-α antagonists: infliximab and etanercept. Food and Drug Administration, Center for Biologics Evaluation and Research. Arthritis Advisory Committee Meeting, August 17, 2001. Available at
  • 2
    Baghai M, Osmon DR, Wolk DM, Wold LE, Haidukewych GJ, Matteson EL. Fatal sepsis in a patient with rheumatoid arthritis treated with etanercept. Mayo Clin Proc 2001; 76: 6536.
  • 3
    Rubin R, Ikonen T, Gummert J, Morris R. The therapeutic prescription for the organ transplant recipient: the linkage of immunosuppression and antimicrobial strategies. Transplant Infect Dis 1999; 1: 2939.
  • 4
    Zhang M, Tracey KJ. Tumor necrosis factor. In: ThompsonA, editor. The cytokine handbook. 3rd ed. San Diego: Academic Press; 1998. p. 51748.
  • 5
    Maini R, St. Clair EW, Breedveld F, Furst D, Kalden J, Weisman M, et al, Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. Infliximab (chimeric anti-tumor necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III study. Lancet 1999; 354: 19329.
  • 6
    Lipsky PE, van der Heijde DMFM, St. Clair EW, Furst DE, Breedveld FC, Kalden JR, et al, for the Anti–Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. Infliximab and methotrexate in the treatment of rheumatoid arthritis. N Engl J Med 2000; 343: 1594602.
  • 7
    Moreland LW, Baumgartner SW, Schiff MH, Tindall EA, Fleischmann RM, Weaver AL, et al. Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein. N Engl J Med 1997; 337: 1417.
  • 8
    Bathon JM, Martin RW, Fleischmann RM, Tesser JR, Schiff MH, Keystone EC, et al. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N Engl J Med 2000; 343: 158693.
  • 9
    Weinblatt ME, Keystone EC, Furst DE, Moreland LW, Weisman MH, Birbara CA, et al. Adalimumab, a fully human anti–tumor necrosis factor α monoclonal antibody, for the treatment of rheumatoid arthritis patients taking concomitant methotrexate: the ARMADA trial. Arthritis Rheum 2003; 48: 3545.
  • 10
    Mease PJ, Goffe BS, Metz J, VanderStoep A, Finck B, Burge DJ. Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial. Lancet 2000; 356: 38590.
  • 11
    Lovell DJ, Giannini EH, Reiff A, Cawkwell GD, Silverman ED, Nocton JJ, et al, Pediatric Rheumatology Collaborative Study Group. Etanercept in children with polyarticular juvenile rheumatoid arthritis. N Engl J Med 2000; 342: 7639.
  • 12
    Present DH, Rutgeerts P, Targan S, Hanauer SB, Mayer L, van Hogezand RA, et al. Infliximab for the treatment of fistulas in patients with Crohn's disease. N Engl J Med 1999; 340: 1398405.
  • 13
    Keane J, Gershon S, Wise RP, Mirabile-Levens E, Kasznica J, Schwieterman WD, et al. Tuberculosis associated with infliximab, a tumor necrosis factor-α neutralizing agent. N Engl J Med 2001; 345: 1098104.
  • 14
    Warris A, Bjorneklett A, Gaustad P. Invasive pulmonary aspergillosis associated with infliximab therapy. N Engl J Med 2001; 344: 1099100.
  • 15
    Spriggs DR, Sherman ML, Michie H, Arthur KA, Imamura K, Wilmore D, et al. Recombinant human tumor necrosis factor administered as a 24-hour intravenous infusion: a phase I and pharmacologic study. J Natl Cancer Inst 1988; 80: 103944.
  • 16
    Beutler B, Milsark IW, Cerami AC. Passive immunization against cachectin/tumor necrosis factor protects mice from lethal effect of endotoxin. Science 1985; 229: 86971.
  • 17
    Silva AT, Bayston KF, Cohen J. Prophylactic and therapeutic effects of a monoclonal antibody to tumor necrosis factor-alpha in experimental gram-negative shock. J Infect Dis 1990; 162: 4217.
  • 18
    Tracey KJ, Fong Y, Hesse DG, Manogue KR, Lee AT, Kuo GC, et al. Anti-cachectin/TNF monoclonal antibodies prevent septic shock during lethal bacteraemia. Nature 1987; 330: 6624.
  • 19
    Fisher CJ Jr, Agosti JM, Opal SM, Lowry SF, Balk RA, Sadoff JC, et al. Treatment of septic shock with the tumor necrosis factor receptor:Fc fusion protein. N Engl J Med 1996; 334: 1697702.
  • 20
    Abraham E, Wunderink R, Silverman H, Perl TM, Nasraway S, Levy H, et al, TNF-alpha MAb Sepsis Study Group. Efficacy and safety of monoclonal antibody to human tumor necrosis factor alpha in patients with sepsis syndrome: a randomized, controlled, double-blind, multicenter clinical trial. JAMA 1995; 273: 93441.
  • 21
    Abraham E, Anzueto A, Gutierrez G, Tessler S, San Pedro G, Wunderink R, et al, NORASEPT II Study Group. Double-blind randomised controlled trial of monclonal antibody to human tumor necrosis factor in treatment of septic shock. Lancet 1998; 351: 92933.
  • 22
    Kaneko H, Yamada H, Mizuno S, Udagawa T, Kazumi Y, Sekikawa K, et al. Role of tumor necrosis factor-alpha in Mycobacterium-induced granuloma formation in tumor necrosis factor-alpha-deficient mice. Lab Invest 1999; 79: 37986.
  • 23
    Kindler V, Sappino AP, Grau GE, Piguet PF, Vassalli P. The inducing role of tumor necrosis factor in the development of bactericidal granulomas during BCG infection. Cell 1989; 56: 73140.
  • 24
    Ehlers S, Benini J, Kutsch S, Endres R, Rietschel ET, Pfeffer K. Fatal granuloma necrosis without exacerbated mycobacterial growth in tumor necrosis receptor p55 gene-deficient mice intravenously infected with mycobacterium avium. Infect Immun 1999; 67: 35719.
  • 25
    Keane J, Gershon SK, Braun MM. Tuberculosis and treatment with infliximab. N Engl J Med 2002; 346: 6236.
  • 26
    Rieder HL, Snider DE Jr, Cauthen GM. Extrapulmonary tuberculosis in the United States. Am Rev Respir Dis 1990; 141: 34751.
  • 27
    Manadan AM, Mohan AK, Cote TR, Siegel JN, Sequeira W, Block JA. Tuberculosis and etanercept treatment [abstract]. Arthritis Rheum 2002; 46 Suppl 9: S166.
  • 28
    Abbott Laboratories. Adalimumab (Humira) package insert. Available at
  • 29
    Dinarello CA, Moldawer LL. Proinflammatory and anti-inflammatory cytokines in rheumatoid arthritis: a primer for clinicians. Thousand Oaks (CA): Amgen, Inc.; 2001. p. 227.
  • 30
    Takashima K, Tateda K, Matsumoto T, Iizawa Y, Nakao M, Yamaguchi K. Role of tumor necrosis factor alpha in pathogenesis of pneumococcal pneumonia in mice. Infect Immun 1997; 65: 25760.
  • 31
    Van der Poll T, Keough CV, Buurman WA, Lowry SF. Passive immunization against tumor necrosis factor-α impairs host defense during pneumococcal pneumonia in mice. Am J Respir Crit Care Med 1997; 155: 6038.
  • 32
    Wellmer A, Gerber J, Ragheb J, Zysk G, Kunst T, Smirnov A, et al. Effect of deficiency of tumor necrosis factor alpha or both of its receptors on Streptococcus pneumoniae central nervous system infection and peritonitis. Infect Immun 2001; 69: 68816.
  • 33
    Havell EA. Evidence that tumor necrosis factor has an important role in antibacterial resistance. J Immunol 1989; 143: 28949.
  • 34
    Slifman NR, Gershon SK, Lee J-H, Edwards ET, Braun MM. Listeria monocytogenes infection as a complication of treatment with tumor necrosis factor α–neutralizing agents. Arthritis Rheum 2003; 48: 31924.
  • 35
    Glück T, Linde H-J, Schölmerich J, Müller-Ladner U, Fiehn C, Bohland P. Anti–tumor necrosis factor therapy and Listeria monocytogenes infection: report of two cases. Arthritis Rheum 2002; 46: 22557.
  • 36
    Nagai H, Guo J, Choi H, Kurup V. Interferon-gamma and tumor necrosis factor-alpha protect mice from invasive aspergillosis. J Infect Dis 1995; 172: 155460.
  • 37
    Roilides E, Dimitriadou-Georgiadou A, Sein T, Kadiltsoglou I, Walsh TJ. Tumor necrosis factor alpha enhances antifungal activities of polymorphonuclear and mononuclear phagocytes against Aspergillus fumigatus. Infect Immun 1998; 66: 59996003.
  • 38
    Mehrad B, Strieter RM, Standiford TF. Role of TNF-α in pulmonary host defense in murine invasive aspergillosis. J Immunol 1999; 162: 163340.
  • 39
    Marty FM, Lee SJ, Alyea EP, Soiffer RJ, Antin JH, Baden LR. Risk of non-Candida invasive fungal infections in allogeneic bone marrow transplant recipients who received infliximab to control severe graft v host disease. 42nd Annual Interscience Conference on Antimicrobial Agents and Chemotherapy. September 2002; San Diego.
  • 40
    Allendoerfer R, Deepe GS Jr. Blockade of endogenous TNF-alpha exacerbates primary and secondary pulmonary histoplasmosis by differential mechanisms. J Immunol 1998; 160: 607282.
  • 41
    Lee J-H, Slifman NR, Gershon SK, Edwards ET, Schwieterman WD, Siegel JN, et al. Life-threatening histoplasmosis complicating immunotherapy with tumor necrosis factor α antagonists infliximab and etanercept. Arthritis Rheum 2002; 46: 256570.
  • 42
    Zaman R, Abbas M. Case report of fatal disseminated histoplasmosis in a patient with rheumatoid arthritis following therapy with etanercept and methotrexate. 40th Annual Meeting of the Infectious Disease Society of America. October 2002; Chicago.
  • 43
    Herring AC, Lee J, McDonald RA, Toews GB, Huffnagle GB. Induction of interleukin-12 and gamma interferon requires tumor necrosis factor alpha for protective T1-cell-mediated immunity to pulmonary Cryptococcus neoformans infection. Infect Immun 2002; 70: 295964.
  • 44
    Starrett W, Czachor J, Dallal M, Drehmer T. Cryptococcal pneumonia following treatment with infliximab for rheumatoid arthritis. 40th Annual Meeting of the Infectious Disease Society of America. October 2002; Chicago.
  • 45
    Shrestha R, Stoller JK, Procop G, Gordon S. Possible zoonotic transmission of cryptococcus neoformans from a pet cockatiel to a patient associated with infliximab. 40th Annual Meeting of the Infectious Disease Society of America. October 2002; Chicago.
  • 46
    Chen W, Havell EA, Harmsen AG. Importance of endogenous tumor necrosis factor alpha and gamma interferon in host resistance against Pneumocystis carinii infection. Infect Immun 1992; 60: 127984.
  • 47
    Jasmer RM, Nahid P, Hopewell PC. Latent tuberculosis infection. N Engl J Med 2002; 347: 18606.
  • 48
    American Thoracic Society. Targeted tuberculin testing and treatment of latent tuberculosis infection. MMWR Recomm Rep 2000 Jun 9; 49(RR-6): 151.
  • 49
    Khan K, Muennig P, Behta M, Zivin JG. Global drug-resistance patterns and the management of latent tuberculosis infection in immigrants to the United States. N Engl J Med 2002; 347: 18509.
  • 50
    Gordin FM, Matts J, Miller C, Brown LS, Hafner R, John SL, et al. A controlled trial of isoniazid in persons with anergy and human immunodeficiency virus infection who are at high risk for tuberculosis. N Engl J Med 1997; 337: 31520.
  • 51
    Elkayam O, Caspi D, Paran D, Reitblat T, Litinsksy I, Yaron M, et al. Effect of anti-TNFalpha therapies on the immunogenecity of pneumococcal vaccination in patients with rheumatic diseases [abstract]. Arthritis Rheum 2002; 46 Suppl 9: S340.
  • 52
    Bergstrom L, Yocum DE, Tesser J, Miller M, Lisse J, Gluck O. Coccidiomycosis (valley fever) occurring during infliximab therapy [abstract]. Arthritis Rheum 2002; 46 Suppl 9: S169.